The CD133+ cell as advanced medicinal product for myocardial and limb ischemia

Dario Bongiovanni, Beatrice Bassetti, Elisa Gambini, Giuseppe Gaipa, Giacomo Frati, Felice Achilli, Paolo Scacciatella, Corrado Carbucicchio, Giulio Pompilio

Research output: Contribution to journalArticle

Abstract

Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133+ cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133+ cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133+ into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133+ manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133+ cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133+ cell as an anti-ischemic AMP.

Original languageEnglish
Pages (from-to)2403-2421
Number of pages19
JournalStem Cells and Development
Volume23
Issue number20
DOIs
Publication statusPublished - Oct 15 2014

Fingerprint

Myocardial Ischemia
Extremities
Adenosine Monophosphate
Paracrine Communication
Cell Lineage
Cell- and Tissue-Based Therapy
Cause of Death
Glycoproteins
Stem Cells
Ischemia
Bone Marrow
Clinical Trials
Morbidity
Antigens
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Hematology
  • Medicine(all)

Cite this

The CD133+ cell as advanced medicinal product for myocardial and limb ischemia. / Bongiovanni, Dario; Bassetti, Beatrice; Gambini, Elisa; Gaipa, Giuseppe; Frati, Giacomo; Achilli, Felice; Scacciatella, Paolo; Carbucicchio, Corrado; Pompilio, Giulio.

In: Stem Cells and Development, Vol. 23, No. 20, 15.10.2014, p. 2403-2421.

Research output: Contribution to journalArticle

@article{1f86d67d16014b24b5eeea3a75bd42eb,
title = "The CD133+ cell as advanced medicinal product for myocardial and limb ischemia",
abstract = "Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133+ cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133+ cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133+ into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133+ manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133+ cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133+ cell as an anti-ischemic AMP.",
author = "Dario Bongiovanni and Beatrice Bassetti and Elisa Gambini and Giuseppe Gaipa and Giacomo Frati and Felice Achilli and Paolo Scacciatella and Corrado Carbucicchio and Giulio Pompilio",
year = "2014",
month = "10",
day = "15",
doi = "10.1089/scd.2014.0111",
language = "English",
volume = "23",
pages = "2403--2421",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "20",

}

TY - JOUR

T1 - The CD133+ cell as advanced medicinal product for myocardial and limb ischemia

AU - Bongiovanni, Dario

AU - Bassetti, Beatrice

AU - Gambini, Elisa

AU - Gaipa, Giuseppe

AU - Frati, Giacomo

AU - Achilli, Felice

AU - Scacciatella, Paolo

AU - Carbucicchio, Corrado

AU - Pompilio, Giulio

PY - 2014/10/15

Y1 - 2014/10/15

N2 - Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133+ cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133+ cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133+ into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133+ manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133+ cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133+ cell as an anti-ischemic AMP.

AB - Ischemic diseases are the major cause of death and morbidity in Western countries. In the last decade, cell therapy has been suggested to be a promising treatment both in acute/chronic myocardial and peripheral ischemia. Different cell lineages have been tested, including endothelial progenitor cells. A subpopulation of bone marrow-derived immature ECPs, expressing the highly conserved stem cell glycoprotein antigen prominin-1 or CD133 marker, was shown to possess pro-angiogenic and antiapoptotic effects on ischemic tissues. The mechanisms implicated in CD133+ cells ability to contribute to neovascularization processes have been attributed to their ability to directly differentiate into newly forming vessels and to indirectly activate pro-angiogenic signaling by paracrine mechanisms. A large body of in vivo experimental evidences has demonstrated the potential of CD133+ cells to reverse ischemia. Moreover, several clinical trials have reported promising beneficial effects after infusion of autologous CD133+ into ischemic heart and limbs exploiting various delivery strategies. These trials have contributed to characterize the CD133+ manufacturing process as an advanced cell product (AMP). The aim of this review is to summarize available experimental and clinical data on CD133+ cells in the context of myocardial and peripheral ischemia, and to focus on the development of the CD133+ cell as an anti-ischemic AMP.

UR - http://www.scopus.com/inward/record.url?scp=84913587691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913587691&partnerID=8YFLogxK

U2 - 10.1089/scd.2014.0111

DO - 10.1089/scd.2014.0111

M3 - Article

C2 - 25014242

AN - SCOPUS:84913587691

VL - 23

SP - 2403

EP - 2421

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 20

ER -